app.rxdatalab.com · Free public feature
Regulatory filings linked to clinical programs and markets. Trials, SEC filings, insider activity, and market data from primary sources.
BioHedge
Hedge fund positioning from Schedule 13D/13G filings. Each position cross-referenced with clinical trial events, regulatory filings, and insider trades. Free public view — the full platform adds company profiles, trial history, competitive landscape, and financing tracker for 500+ biotech companies.
Activity Summary
Multi-Fund Activity
Companies with two or more institutional investors filing in the same period.
Filing Volume by Week
|
Filed
|
Fund | Company | Position | Gap |
|---|---|---|---|---|
|
Apr 17, 2026
Event: 04/15/2026
Filed: Apr 17, 2026 |
WVE
Wave Life Sciences Ltd.
|
owns 17.1% ▼-0.4 | 18d | |
|
WVE
Wave Life Sciences Ltd.
17.1%
▼-0.4
18d
|
||||
|
Apr 16, 2026
Event: 04/16/2026
Filed: Apr 16, 2026 |
ONC
BEONE MEDICINES LTD-ADR
|
owns 8.0% | — | |
|
ONC
BEONE MEDICINES LTD-ADR
8.0%
|
||||
|
Apr 16, 2026
Event: 04/16/2026
Filed: Apr 16, 2026 |
LTRN
Lantern Pharma Inc.
|
owns 7.4% ▼-1.2 | 52d | |
|
LTRN
Lantern Pharma Inc.
7.4%
▼-1.2
52d
|
||||
|
Apr 15, 2026
Event: 04/14/2026
Filed: Apr 15, 2026 |
VOR
Vor Biopharma Inc.
|
owns 19.9% | 5d | |
|
VOR
Vor Biopharma Inc.
19.9%
5d
|
||||
|
Apr 15, 2026
Event: 04/15/2026
Filed: Apr 15, 2026 |
PHGE
BiomX Inc.
|
owns 10.0% | 408d | |
|
PHGE
BiomX Inc.
10.0%
408d
|
||||
|
Apr 15, 2026
Event: 04/08/2026
Filed: Apr 15, 2026 |
ZYME
Zymeworks Inc.
|
owns 5.4% NEW | — | |
|
ZYME
Zymeworks Inc.
5.4%
NEW
|
||||
|
Apr 14, 2026
Event: 04/10/2026
Filed: Apr 14, 2026 |
ABSI
ABSCI CORP
|
owns 4.9% ▼-0.5 | 19d | |
|
ABSI
ABSCI CORP
4.9%
▼-0.5
19d
|
||||
|
Apr 13, 2026
Event: 04/06/2026
Filed: Apr 13, 2026 |
RLAY
Relay Therapeutics, Inc.
|
owns 10.0% NEW | 25d | |
|
RLAY
Relay Therapeutics, Inc.
10.0%
NEW
25d
|
||||
|
Apr 13, 2026
Event: 02/17/2026
Filed: Apr 13, 2026 |
ACET
Adicet Bio, Inc.
|
owns 12.3% ▲2.4 | 55d | |
|
ACET
Adicet Bio, Inc.
12.3%
▲2.4
55d
|
||||
|
Apr 10, 2026
Event: 04/09/2026
Filed: Apr 10, 2026 |
VOR
Vor Biopharma Inc.
|
owns 19.9% | 2d | |
|
VOR
Vor Biopharma Inc.
19.9%
2d
|
||||
|
Apr 10, 2026
Event: 04/08/2026
Filed: Apr 10, 2026 |
D
OrbiMed
|
ACET
Adicet Bio, Inc.
|
owns 8.8% | — |
|
ACET
Adicet Bio, Inc.
8.8%
|
||||
|
Apr 8, 2026
Event: 04/06/2026
Filed: Apr 8, 2026 |
VOR
Vor Biopharma Inc.
|
owns 19.9% | 7d | |
|
VOR
Vor Biopharma Inc.
19.9%
7d
|
||||
|
Apr 7, 2026
Event: 03/31/2026
Filed: Apr 7, 2026 |
OKUR
OnKure, Inc.
|
owns 9.9% NEW | — | |
|
OKUR
OnKure, Inc.
9.9%
NEW
|
||||
|
Apr 7, 2026
Event: 03/31/2026
Filed: Apr 7, 2026 |
ACRS
Aclaris Therapeutics, Inc.
|
owns 6.3% NEW | — | |
|
ACRS
Aclaris Therapeutics, Inc.
6.3%
NEW
|
||||
|
Apr 6, 2026
Event: 03/30/2026
Filed: Apr 6, 2026 |
ZLAB
Zai Lab Ltd
|
owns 5.2% NEW | — | |
|
ZLAB
Zai Lab Ltd
5.2%
NEW
|
||||
|
Apr 6, 2026
Event: 04/06/2026
Filed: Apr 6, 2026 |
ADCT
ADC Therapeutics SA
|
owns 9.9% ▼-2.8 | 48d | |
|
ADCT
ADC Therapeutics SA
9.9%
▼-2.8
48d
|
||||
|
Apr 2, 2026
Event: 03/31/2026
Filed: Apr 2, 2026 |
MLTX
MoonLake Immunotherapeutics
|
owns 22.3% ▼-5.4 | 143d | |
|
MLTX
MoonLake Immunotherapeutics
22.3%
▼-5.4
143d
|
||||
|
Apr 2, 2026
Event: 03/26/2026
Filed: Apr 2, 2026 |
KPTI
Karyopharm Therapeutics Inc.
|
owns 9.9% NEW | — | |
|
KPTI
Karyopharm Therapeutics Inc.
9.9%
NEW
|
||||
|
Apr 1, 2026
Event: 03/30/2026
Filed: Apr 1, 2026 |
NMRA
Neumora Therapeutics, Inc.
|
owns 18.7% | — | |
|
NMRA
Neumora Therapeutics, Inc.
18.7%
|
||||
|
Apr 1, 2026
Event: 03/30/2026
Filed: Apr 1, 2026 |
VOR
Vor Biopharma Inc.
|
owns 19.9% | 16d | |
|
VOR
Vor Biopharma Inc.
19.9%
16d
|
||||
|
Mar 31, 2026
Event: 03/31/2026
Filed: Mar 31, 2026 |
COGT
Cogent Biosciences, Inc.
|
owns 8.6% ▼-1.3 | 68d | |
|
COGT
Cogent Biosciences, Inc.
8.6%
▼-1.3
68d
|
||||
|
Mar 30, 2026
Event: 03/26/2026
Filed: Mar 30, 2026 |
WVE
Wave Life Sciences Ltd.
|
owns 17.5% ▲4.1 | 105d | |
|
WVE
Wave Life Sciences Ltd.
17.5%
▲4.1
105d
|
||||
|
Mar 30, 2026
Event: 03/23/2026
Filed: Mar 30, 2026 |
XNCR
Xencor Inc
|
owns 6.5% NEW | — | |
|
XNCR
Xencor Inc
6.5%
NEW
|
||||
|
Mar 27, 2026
Event: 03/26/2026
Filed: Mar 27, 2026 |
Agreements · Fairmount Funds Management LLC's Fund II entered into a lock-up agreement for 60 days, restricting the sale of Apogee Therapeutics securities without consent from Jefferies LLC, in connection with the Company's public offering. The Reporting Persons did not participate in the offering. |
owns 10.0% | 64d | |
|
10.0%
64d
Fairmount Funds Management LLC's Fund II entered into a lock-up agreement for 60 days, restricting the sale of Apogee Therapeutics securities without consent from Jefferies LLC, in connection with the Company's public offering. The Reporting Persons did not participate in the offering. |
||||
|
Mar 26, 2026
Event: 03/24/2026
Filed: Mar 26, 2026 |
ABSI
ABSCI CORP
|
owns 5.4% ▼-1.1 | 331d | |
|
ABSI
ABSCI CORP
5.4%
▼-1.1
331d
|
||||
Understanding Schedule 13D and 13G Filings
Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.
Schedule 13D (Activist)
Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.
Schedule 13G (Passive)
Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.
Gap column: Days since previous filing for the same fund+company pair.
Data source: SEC EDGAR. Filings typically available within 4 hours of submission.
This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.
Intelligence Platform
Every event, in context.
Cross-reference each company's trial history, SEC filings, insider trades, and fund positioning in one view. Traceable to primary sources.